MS drug levels in breast milk under study for nursing moms

NCT ID NCT06444113

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how much of the multiple sclerosis drug ofatumumab gets into breast milk. About 24 women with relapsing MS who are breastfeeding and starting or restarting ofatumumab will provide milk samples. The goal is to measure drug concentrations, which may help guide future breastfeeding recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ofatumumab

What this could lead to

If successful, this study could help doctors give better advice to women with MS who want to breastfeed while on ofatumumab.

What could go wrong

This is a small, observational study (24 participants) that only measures drug levels in milk, not safety or long-term effects on babies. Results may not apply to all women.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Womens Hospital

    Brookline, Massachusetts, 02445, United States

  • Northwestern Medicine Northwestern University

    Winfield, Illinois, 60190, United States

  • Novartis Investigative Site

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    Bochum, 44791, Germany

  • Novartis Investigative Site

    Hamburg, 22179, Germany

  • Novartis Investigative Site

    Tübingen, 72076, Germany

  • Novartis Investigative Site

    Foggia, FG, 71122, Italy

  • Novartis Investigative Site

    Bialystok, 15 276, Poland

  • Novartis Investigative Site

    Kielce, 25 726, Poland

  • Novartis Investigative Site

    Cambridge, CB2 0QQ, United Kingdom

  • Novartis Investigative Site

    London, NW1 2BU, United Kingdom

  • Novartis Investigative Site

    Oxford, OX3 9DU, United Kingdom

  • Novartis Investigative Site

    Salford, M6 8HD, United Kingdom

  • UC Health Neuroscience Ctr

    Aurora, Colorado, 80045, United States

  • UCSF

    San Francisco, California, 94115, United States